image: Safety, effectiveness, stability and industrial production capacity of nanomaterials in the GI.
Credit: Tianfeng Chen
Published in the KeAi journal Nano Biomedicine and Engineering, a new review by researchers from Jinan University describes how oral nanomaterial formulations serve as promising carriers for gastrointestinal (GI) disease treatment.
"Oral delivery is the most patient-friendly route for GI therapy, but conventional drugs often struggle with low solubility, acid degradation, poor absorption and insufficient targeting," says co-corresponding author Tianfeng Chen. "Nanomaterials effectively address these drawbacks by shielding drugs from harsh GI conditions, boosting permeability and enabling site-specific intestinal delivery."
Nanomaterials are divided into metallic and non-metallic categories. Metallic nanomaterials, including TiO₂, Ag, Au, Cu and Zn nanostructures, show high stability and strong antimicrobial activity, but face biosafety concerns such as ion release, intestinal barrier damage, gut microbiota dysregulation and long-term accumulation.
In contrast, non-metallic nanomaterials—including silica, polymer nanoparticles, carbon nanomaterials, liposomes and selenium nanoparticles (SeNPs)—present better biocompatibility, tunable biodegradability and milder interactions with the GI microenvironment.
"Selenium nanoparticles are particularly attractive for their intrinsic antioxidant, anti-inflammatory and gut-protective effects, as well as their scalability for industrial production," adds Chen.
Despite great progress, however, challenges remain in large-scale and reproducible synthesis, long-term biosafety, residual impurity control, batch-to-batch consistency and compliance with clinical GMP standards.
"From safety and biocompatibility to scalability and clinical feasibility, non-metallic nanomaterials, especially SeNPs, polymers and liposomes, offer a more practical route for future oral gastrointestinal therapeutics," says co-corresponding author Hongwei Huang.
According to the authors, future work would focus on rational structural design, stimulus-responsive controlled release, standardized biosafety evaluation, real-time GI tracking and intelligent manufacturing to speed up clinical translation.
###
Contact the author: Tianfeng Chen, Hongwei Huang College of Pharmacy, Institute of Nanotechnology And Intelligence (inAI),State Key Laboratory of Bioactive Molecules and Druggability Assessment,Jinan University;Department of Pharmacy and General Surgery, Puning People’s Hospital(Guangdong Postdoctoral Innovation Practice Base, Jinan University), Guangzhou, Guangdong, China , sincos90@163.com
The publisher KeAi was established by Elsevier and China Science Publishing & Media Ltd to unfold quality research globally. In 2013, our focus shifted to open access publishing. We now proudly publish more than 200 world-class, open access, English language journals, spanning all scientific disciplines. Many of these are titles we publish in partnership with prestigious societies and academic institutions, such as the National Natural Science Foundation of China (NSFC).
Journal
Nano Biomedicine and Engineering
Article Title
Oral nanomaterial formulations for gastrointestinal therapeutics: Promises and challenges on the path to clinical translation
COI Statement
The author Tianfeng Chen is Associate Editor for Nano Biomedicine and Engineering and was not involved in the editorial review or the decision to publish this article.